In 2022, Kasenda and group, for the first time in a phase I trial, clinically assessed the capacity of EGFR-targeted immunoliposomes in delivering the cargo to brain tissue in patients with relapsed EGFR amplified glioblastomas. Here, EGFR is linked to glioblastoma.